Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against SARS-CoV-2.
Pol Arch Intern Med
; 131(3): 226-232, 2021 03 30.
Article
in English
| MEDLINE | ID: covidwho-1158486
ABSTRACT
INTRODUCTION:
According to the current data, there has been no increase in the incidence of COVID19 in patients with inflammatory bowel disease (IBD).OBJECTIVES:
The available data are based on symptomatic cases and do not include the asymptomatic ones. To measure the exact infection rate, we initiated a study that aimed to assess the seroprevalence of anti-SARSCoV2 antibodies in IBD. PATIENTS ANDMETHODS:
A total of 864 individuals were enrolled in the study, including 432 patients with IBD (290 with Crohn disease and 142 with ulcerative colitis) and 432 controls without IBD (healthcare professionals) matched for age and sex. Serum samples were prospectively collected, and the presence of anti-SARSCoV2 immunoglobulin (Ig) G and IgM + IgA antibodies were measured using the enzymelinked immunoassay method (Vircell Microbiologists).RESULTS:
A significantly higher percentage of positive results for anti-SARSCoV2 antibodies, both in the IgG and IgM + IgA class, was found in patients with IBD (4.6% and 6%, respectively, compared with 1.6% and 1.1%, respectively, in controls; both P values <0.05). No patient had symptomatic COVID19. There was no association among patients' age, sex, drugs used for IBD, or disease activity and the occurrence of IgG antibodies.CONCLUSION:
Patients with IBD may be at higher risk of developing SARSCoV2 infection, defined as the presence of elevated levels of anti-SARSCoV2 IgG antibodies, but not of having a symptomatic and / or severe course of COVID19 compared with healthcare professionals without IBD.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Inflammatory Bowel Diseases
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Pol Arch Intern Med
Year:
2021
Document Type:
Article
Affiliation country:
Pamw.15796
Similar
MEDLINE
...
LILACS
LIS